TEPANIL TEN-TAB

Clinical safety rating: caution

Comprehensive clinical and safety monograph for TEPANIL TEN-TAB (TEPANIL TEN-TAB).

How it works

TEPANIL TEN-TAB (diethylpropion hydrochloride controlled-release) is a sympathomimetic amine anorectic agent. It acts primarily on the central nervous system to suppress appetite, likely via stimulation of the hypothalamus to release norepinephrine and dopamine, leading to decreased food intake. The exact molecular mechanism involves inhibition of norepinephrine and dopamine reuptake in the synaptic cleft, increasing their concentrations in the central nervous system.

What the body does with it

Metabolism	Diethylpropion is extensively metabolized in the liver via N-dealkylation, hydroxylation, and conjugation. Major metabolites include ethylaminopropiophenone and other active metabolites. The cytochrome P450 enzyme system is involved, but specific isoforms have not been fully elucidated.
Excretion	Renal excretion accounts for 60-80% of the dose. Biliary/fecal elimination is approximately 10-20%.
Half-life	Terminal elimination half-life is 4-6 hours. Clinical context: Steady state is achieved within 1-2 days.
Protein binding	Plasma protein binding is 90-95%, primarily to albumin.
Volume of Distribution	Volume of distribution is 3-4 L/kg, indicating extensive tissue distribution.
Bioavailability	Oral bioavailability is 80-90% due to first-pass metabolism (approximately 5-10% metabolized).
Onset of Action	Oral immediate-release: 30-60 minutes. TEPANIL TEN-TAB (extended-release): 1-2 hours.
Duration of Action	Oral immediate-release: 4-6 hours. TEPANIL TEN-TAB: 8-12 hours due to extended-release formulation.

Classification & Brands

Dosing & administration

25 mg orally three times daily, 1 hour before meals; for sustained-release, 75 mg orally once daily in the morning.

Dosage form	TABLET, EXTENDED RELEASE
Renal impairment	Contraindicated in severe renal impairment (GFR <30 mL/min); no specific dose adjustment for mild-to-moderate impairment.
Liver impairment	Contraindicated in severe hepatic impairment; caution and reduced dose may be considered for Child-Pugh B or C, but no validated guidelines.
Pediatric use	Not recommended for patients under 16 years of age; safety and efficacy not established.
Geriatric use	Initiate at lower doses due to increased sensitivity; avoid use in elderly due to potential for adverse effects (cardiovascular, CNS stimulation, abuse liability).

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for TEPANIL TEN-TAB (TEPANIL TEN-TAB).

Breastfeeding	Diethylpropion and its metabolites are excreted in human milk. M/P ratio unknown. Potential for serious adverse reactions in nursing infants, including irritability, sleep disturbance, and cardiovascular effects. Contraindicated in breastfeeding; bottle-feed or discontinue drug.
Teratogenic Risk	First trimester: Limited human data; animal studies not adequate. Risk cannot be excluded. Second and third trimesters: Avoid use due to potential for fetal tachycardia, decreased fetal growth, and preterm labor. Anorexiants may cause fetal cocaine-like effects. Anorexiant use associated with increased risk of premature birth, low birth weight, and neonatal withdrawal (irritability, tremors).

Warnings & precautions

■ FDA Black Box Warning

TEPANIL TEN-TAB has a high potential for abuse and dependence. It should not be used in combination with other anorectic agents or for long-term treatment. The drug is contraindicated in patients with a history of drug abuse.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to diethylpropion or other sympathomimetic amines","History of drug abuse","Cardiovascular disease including coronary artery disease, arrhythmias, heart failure, hypertension","Hyperthyroidism","Glaucoma","Agitated states or history of seizures","During or within 14 days of monoamine oxidase inhibitor (MAOI) use","Concurrent use with other anorectic agents","Pregnancy and lactation (category B/C; not recommended)"]

Clinical Precautions

Precautions

["Risk of serious cardiovascular events including hypertension, palpitations, tachycardia, and arrhythmias","Pulmonary hypertension reported","Seizures in epileptic patients","May impair ability to drive or operate machinery","Dependence and tolerance may develop","Use caution in patients with glaucoma, hyperthyroidism, or anxiety states","Monitor blood pressure and heart rate regularly"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

TEPANIL TEN-TAB

Clinical safety rating: caution

Comprehensive clinical and safety monograph for TEPANIL TEN-TAB (TEPANIL TEN-TAB).

How it works

What the body does with it

Metabolism	Diethylpropion is extensively metabolized in the liver via N-dealkylation, hydroxylation, and conjugation. Major metabolites include ethylaminopropiophenone and other active metabolites. The cytochrome P450 enzyme system is involved, but specific isoforms have not been fully elucidated.
Excretion	Renal excretion accounts for 60-80% of the dose. Biliary/fecal elimination is approximately 10-20%.
Half-life	Terminal elimination half-life is 4-6 hours. Clinical context: Steady state is achieved within 1-2 days.
Protein binding	Plasma protein binding is 90-95%, primarily to albumin.
Volume of Distribution	Volume of distribution is 3-4 L/kg, indicating extensive tissue distribution.
Bioavailability	Oral bioavailability is 80-90% due to first-pass metabolism (approximately 5-10% metabolized).
Onset of Action	Oral immediate-release: 30-60 minutes. TEPANIL TEN-TAB (extended-release): 1-2 hours.
Duration of Action	Oral immediate-release: 4-6 hours. TEPANIL TEN-TAB: 8-12 hours due to extended-release formulation.

Classification & Brands

Dosing & administration

25 mg orally three times daily, 1 hour before meals; for sustained-release, 75 mg orally once daily in the morning.

Dosage form	TABLET, EXTENDED RELEASE
Renal impairment	Contraindicated in severe renal impairment (GFR <30 mL/min); no specific dose adjustment for mild-to-moderate impairment.
Liver impairment	Contraindicated in severe hepatic impairment; caution and reduced dose may be considered for Child-Pugh B or C, but no validated guidelines.
Pediatric use	Not recommended for patients under 16 years of age; safety and efficacy not established.
Geriatric use	Initiate at lower doses due to increased sensitivity; avoid use in elderly due to potential for adverse effects (cardiovascular, CNS stimulation, abuse liability).

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for TEPANIL TEN-TAB (TEPANIL TEN-TAB).

Breastfeeding	Diethylpropion and its metabolites are excreted in human milk. M/P ratio unknown. Potential for serious adverse reactions in nursing infants, including irritability, sleep disturbance, and cardiovascular effects. Contraindicated in breastfeeding; bottle-feed or discontinue drug.
Teratogenic Risk	First trimester: Limited human data; animal studies not adequate. Risk cannot be excluded. Second and third trimesters: Avoid use due to potential for fetal tachycardia, decreased fetal growth, and preterm labor. Anorexiants may cause fetal cocaine-like effects. Anorexiant use associated with increased risk of premature birth, low birth weight, and neonatal withdrawal (irritability, tremors).